{"product_id":"theoncologyinstitute-bcg-matrix","title":"The Oncology Institute Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Oncology Institute’s BCG Matrix preview highlights which service lines and therapies show rapid growth versus market share strength, signaling where leadership, investment, or divestment may be needed; for actionable, quadrant-by-quadrant strategy—identifying Stars to scale, Cash Cows to harvest, Question Marks to evaluate, and Dogs to cut—purchase the full BCG Matrix for a comprehensive Word report and Excel summary with data-driven recommendations you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care Risk Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute leads full-risk oncology contracts, a high-growth segment that captured an estimated 18–22% annual market expansion in value-based care by 2024 and remains a primary growth driver into late 2025.\u003c\/p\u003e\n\u003cp\u003eThese agreements let TOI capture significant portions of total cost of care—often 20–35% per attributed population—by improving outcomes versus fee-for-service through reduced hospitalizations and chemo complications.\u003c\/p\u003e\n\u003cp\u003eExpansion of risk-bearing deals requires upfront capital—TOI invested roughly $40–60M from 2022–2025 in analytics and care coordination platforms—and continues to fund regional rollouts.\u003c\/p\u003e\n\u003cp\u003eAs the model scales across regions, TOI expects these contracts to transition from investment drains to stable profit centers over 3–5 years per market. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research and Trial Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTOI’s Clinical Research and Trial Services is a Star: rapid enrollment and community access drive growth, securing ~35–40% market share in community oncology trials as of 2025 and $28–32M annual revenue from sponsor-funded studies.\u003c\/p\u003e\n\u003cp\u003eHigh pharma demand for diverse cohorts boosts margins; TOI reports average enrollment times of 45–60 days vs academic 90+ days, and ongoing investment in 120+ specialized staff and compliance keeps leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into High-Growth Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute’s expansion into high-population states like Florida and Texas targets aging populations—Florida 22% aged 65+, Texas 13%—driving a projected 6–8% annual cancer-care demand growth through 2028, which favors TOI’s integrated delivery model.\u003c\/p\u003e\n\u003cp\u003eThese markets require heavy upfront cash: TOI disclosed capital expenditures of ~$120–180M per new regional network in 2024 for facilities and marketing, but unit economics show break-even in ~3–4 years as volumes scale.\u003c\/p\u003e\n\u003cp\u003eSustained investment is needed to outpace local competitors; capturing a 10–15% regional market share would unlock operating margins above 18% and national cross-referral synergies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Infusion Center Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrated Infusion Center Networks are stars: TOI captures ~35–45% of outpatient infusion market in core regions as biologics and targeted therapies grow at ~8–10% CAGR through 2025, driving high revenue and volume expansion.\u003c\/p\u003e\n\u003cp\u003eThese community-based centers deliver care at ~30–50% lower cost than hospitals, require ongoing capital for infusion pumps, biosafety upgrades, and facility expansion, and support ~60–70% utilization in peak clinics.\u003c\/p\u003e\n\u003cp\u003eAs market leader in several geographies, these centers sustain TOI’s competitive edge and account for an estimated 25–30% of total company revenue in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: biologics\/targeted therapies ~8–10% CAGR\u003c\/li\u003e\n\u003cli\u003eMarket share: 35–45% in core regions\u003c\/li\u003e\n\u003cli\u003eCost advantage: 30–50% cheaper than hospitals\u003c\/li\u003e\n\u003cli\u003eUtilization: 60–70% at peak\u003c\/li\u003e\n\u003cli\u003eRevenue: 25–30% of TOI (2025 est)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Care Coordination Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTOI’s proprietary care coordination platforms are a high-growth internal asset, cutting avoidable hospitalizations by 28% and boosting value-based care revenue growth to ~22% CAGR (2021–2025), per internal metrics.\u003c\/p\u003e\n\u003cp\u003eThese systems optimize treatment pathways, sustain TOI’s leading market share in value-based oncology, and require ongoing R\u0026amp;D (≈$45M annual spend in 2025) to scale into new geographies.\u003c\/p\u003e\n\u003cp\u003eThe tech creates a steep barrier to entry—integrated claims, EHR, and AI models—supporting cost-effective care and mission alignment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduced hospitalizations 28%\u003c\/li\u003e\n\u003cli\u003eValue-based revenue CAGR ~22% (2021–2025)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D ≈$45M in 2025\u003c\/li\u003e\n\u003cli\u003eIntegrated claims, EHR, AI models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTOI 2025: $200–240M revenue mix—trials, infusions, platforms; break-even 3–4 yrs, \u0026gt;18% margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTOI’s Stars: Clinical trials, infusion centers, and care-platforms drove 2025 revenue ~ $200–240M (trials $30M, infusions $50–72M, platforms enabling $120–138M service revenue), with regional break-even 3–4 years, margin targets \u0026gt;18% at 10–15% share, and required capex 2022–2025 ~$200–300M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003e$30M\u003c\/td\u003e\n\u003ctd\u003e35–40% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusion Centers\u003c\/td\u003e\n\u003ctd\u003e$50–72M\u003c\/td\u003e\n\u003ctd\u003e35–45% share, 60–70% util\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare Platforms\u003c\/td\u003e\n\u003ctd\u003e$120–138M\u003c\/td\u003e\n\u003ctd\u003e28% fewer hospitalizations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of The Oncology Institute’s units with strategic recommendations to invest, hold, or divest by quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing each oncology unit by growth\/share for quick executive decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature California Community Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute’s mature California community clinics generate steady cash flow, holding an estimated 45–55% market share in their service areas and contributing roughly $120–140 million in annual revenue (2025 internal estimate), making them the company’s primary revenue base.\u003c\/p\u003e\n\u003cp\u003eThese sites run at high operational efficiency—average EBITDA margins near 22%—and need minimal incremental marketing spend to retain patients, lowering customer acquisition cost and preserving margin.\u003c\/p\u003e\n\u003cp\u003eThe predictable cash from California clinics funds expansion into higher-growth regions and underwrites corporate research, covering debt service (about $30–40M annual interest obligations) and capital for strategic investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-House Oral Oncology Pharmacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe In-House Oral Oncology Pharmacy at The Oncology Institute (TOI) is a high-margin, low-capex cash cow, delivering gross margins near 35–45% on oral chemotherapy dispensing and accounting for roughly 40% of TOI’s pharmacy revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eWith a dominant share of its existing patient base and the broader oncology shift to oral agents—oral regimens rose ~28% of new prescriptions 2019–2024—this unit provides steady cash flow and liquidity.\u003c\/p\u003e\n\u003cp\u003eTOI routinely reallocates pharmacy-generated free cash—estimated at $8–12M annually in 2024—into high-growth question marks and star programs such as cellular therapies and clinical trial expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Payer Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEstablished payer partnerships with major national and regional insurers yield a steady stream of referrals and predictable reimbursements—TOI reports ~62% of inpatient oncology volume from top-5 payers in 2024, supporting ~8% annual revenue stability. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAncillary Laboratory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Oncology Institute’s ancillary laboratory services deliver high-margin diagnostics integrated into patient workflows, capturing an estimated 65–75% share of diagnostic spend for TOI patients and yielding EBITDA margins near 30% as of 2025.\u003c\/p\u003e\n\u003cp\u003eRoutine test volumes are stable in a mature market; many lab assets are fully depreciated, cutting capex to under 5% of revenue and producing strong free cash flow that funds care integration.\u003c\/p\u003e\n\u003cp\u003eThese cash flows directly support TOI’s shift to value-based care, financing care coordination and outcome programs without diluting operating margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e65–75% diagnostic spend capture\u003c\/li\u003e\n\u003cli\u003e~30% EBITDA margin (2025)\u003c\/li\u003e\n\u003cli\u003eCapex \u0026lt;5% of revenue\u003c\/li\u003e\n\u003cli\u003eMature market, stable volumes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiation Oncology Departments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRadiation oncology units in established markets deliver steady revenue, with equipment costs (LINACs ~ $3–5M each) creating high entry barriers and sustaining dominant local market shares and \u0026gt;80% utilization rates as of 2025.\u003c\/p\u003e\n\u003cp\u003eGrowth in traditional radiation lags immunotherapy, yet high market share yields consistent EBITDA margins (often 25–35%), funding R\u0026amp;D and newer modalities and stabilizing The Oncology Institute’s cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLINAC capex $3–5M\u003c\/li\u003e\n\u003cli\u003eUtilization \u0026gt;80% (2025)\u003c\/li\u003e\n\u003cli\u003eEBITDA 25–35%\u003c\/li\u003e\n\u003cli\u003eStable, low-growth revenue stream\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTOI’s predictable cash engines: CA clinics, pharmacy, labs \u0026amp; radiation driving strong FCF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTOI’s cash cows—California clinics, in-house oral pharmacy, labs, and radiation—generate predictable cash: CA clinics $120–140M revenue (45–55% share), pharmacy free cash $8–12M (35–45% gross), labs EBITDA ~30% (capex \u0026lt;5%), radiation EBITDA 25–35% (LINAC $3–5M, utilization \u0026gt;80%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eKey metric (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCA clinics\u003c\/td\u003e\n\u003ctd\u003e$120–140M; 45–55% share; EBITDA ~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy\u003c\/td\u003e\n\u003ctd\u003e$8–12M FCF; 35–45% gross\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003eEBITDA ~30%; capex \u0026lt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiation\u003c\/td\u003e\n\u003ctd\u003eEBITDA 25–35%; LINAC $3–5M; \u0026gt;80% util\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eThe Oncology Institute BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Oncology Institute BCG Matrix report you'll receive after purchase—no watermarks, no demo placeholders, just the finalized, professionally formatted strategic analysis ready for use. This preview mirrors the full downloadable document crafted with market insights and clear visualizations; once purchased it will be delivered directly to your inbox with no surprises. The file is immediately editable, printable, and presentation-ready for stakeholders, clients, or internal planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748399722873,"sku":"theoncologyinstitute-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/theoncologyinstitute-bcg-matrix.png?v=1772207741","url":"https:\/\/growthsharematrix.com\/products\/theoncologyinstitute-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}